Prostanoid therapies in the management of pulmonary arterial hypertension

References

• HoeperMMBogaardHJCondliffeRDefinitions and diagnosis of pulmonary hypertensionJ Am Coll Cardiol20136225 SupplD42D5024355641
   PubMed Web of Science ®Google Scholar
• D’AlonzoGEBarstRJAyresSMSurvival in patients with primary pulmonary hypertension. Results from a national prospective registryAnn Intern Med199111553433491863023
   PubMed Web of Science ®Google Scholar
• BenzaRLMillerDPBarstRJBadeschDBFrostAEMcGoonMDAn evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL RegistryChest2012142244845622281797
   PubMed Web of Science ®Google Scholar
• BarstRJRubinLJLongWAA comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionN Engl J Med199633452963018532025
   PubMed Web of Science ®Google Scholar
• GalièNManesANegroLPalazziniMBacchi-ReggianiMLBranziAA meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEur Heart J200930439440319155250
   PubMed Web of Science ®Google Scholar
• RyersonCJNayarSSwistonJRSinDDPharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysisRespir Res2010111220113497
   PubMed Web of Science ®Google Scholar
• GalièNCorrisPAFrostAUpdated treatment algorithm of pulmonary arterial hypertensionJ Am Coll Cardiol20136225 SupplD60D7224355643
   PubMed Web of Science ®Google Scholar
• ZhengYYangTChenGHuEGuQXiongCProstanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomesEur J Clin Pharmacol2014701132124026627
   PubMed Web of Science ®Google Scholar
• ChristmanBWMcPhersonCDNewmanJHAn imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertensionN Engl J Med1992327270751603138
   PubMed Web of Science ®Google Scholar
• TuderRMCoolCDGeraciMWProstacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertensionAm J Respir Crit Care Med199915961925193210351941
   PubMed Web of Science ®Google Scholar
• WhittleBJSilversteinAMMottolaDMClappLHBinding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonistBiochem Pharmacol2012841687522480736
   PubMed Web of Science ®Google Scholar
• LaiYJPullamsettiSSDonyERole of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertensionAm J Respir Crit Care Med2008178218819618467507
   PubMed Web of Science ®Google Scholar
• ClappLHFinneyPTurcatoSTranSRubinLJTinkerADifferential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary arteryAm J Respir Cell Mol Biol200226219420111804870
   PubMed Web of Science ®Google Scholar
• FalcettiEHallSMPhillipsPGSmooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertensionAm J Respir Crit Care Med201018291161117020622039
   PubMed Web of Science ®Google Scholar
• MoncadaSHiggsEAVaneJRHuman arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregationLancet197718001182063657
   PubMed Web of Science ®Google Scholar
• ZhouWHashimotoKGoleniewskaKProstaglandin I2 analogs inhibit proinflammatory cytokine production and T-cell stimulatory function of dendritic cellsJ Immunol2007178270271017202330
   PubMed Web of Science ®Google Scholar
• RaychaudhuriBMalurABonfieldTLThe prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophagesJ Biol Chem200227736333443334812082102
   PubMed Web of Science ®Google Scholar
• FontanaMOlschewskiHOlschewskiASchluterKDTreprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytesBr J Pharmacol2007151677978617533419
   PubMed Web of Science ®Google Scholar
• Flolan^® [package insert]LondonGlaxoSmithKline2011 Available from: https://http://www.gsksource.com/gskprm/htdocs/documents/FLOLAN.PDFAccessed September 1, 2014
   Google Scholar
• Veletri^® [package insert]AllschwilActelion Pharmaceuticals Ltd2012 Available from: http://www.veletri.com/pdf/veletri_full_prescribing_information_2nd_gen.pdfAccessed September 1, 2014
   Google Scholar
• NicolasLBGutierrezMMDingemanseJComparative pharmacokinetic, pharmacodynamic, safety, and tolerability profiles of 3 different formulations of epoprostenol sodium for injection in healthy menClin Ther201335444044923498778
   PubMed Web of Science ®Google Scholar
• SitbonODelcroixMBergotEEPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertensionAm Heart J2014167221021724439982
   PubMed Web of Science ®Google Scholar
• ChinKMBadeschDBRobbinsIMTwo formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized studyAm Heart J20141672218225.e124439983
   PubMed Web of Science ®Google Scholar
• SitbonOHumbertMNunesHLong-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survivalJ Am Coll Cardiol200240478078812204511
   PubMed Web of Science ®Google Scholar
• WatkinsWDPetersonMBCroneRKShannonDCLevineLProstacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertensionLancet19801817710836103414
   PubMed Web of Science ®Google Scholar
• LockJEOlleyPMCoceaniFSwyerPRRoweRDUse of prostacyclin in persistent fetal circulationLancet197918130134387797
   PubMed Web of Science ®Google Scholar
• SzczeklikJSzczeklikANizankowskiRProstacyclin for pulmonary hypertensionLancet19802820310766107694
   PubMed Web of Science ®Google Scholar
• GuadagniDNIkramHMaslowskiAHHaemodynamic effects of prostacyclin (PGI2) in pulmonary hypertensionBr Heart J19814543853887013775
   PubMedGoogle Scholar
• RubinLJGrovesBMReevesJTFrosolonoMHandelFCatoAEProstacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertensionCirculation19826623343387046988
   PubMed Web of Science ®Google Scholar
• HigenbottamTWheeldonDWellsFWallworkJLong-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)Lancet198418385104610476143976
   PubMed Web of Science ®Google Scholar
• JonesDKHigenbottamTWWallworkJTreatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)Br Heart J19875732702783552006
   PubMedGoogle Scholar
• RubinLJMendozaJHoodMTreatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trialAnn Intern Med199011274854912107780
   PubMed Web of Science ®Google Scholar
• BadeschDBTapsonVFMcGoonMDContinuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialAnn Intern Med2000132642543410733441
   PubMed Web of Science ®Google Scholar
• McLaughlinVVShillingtonARichSSurvival in primary pulmonary hypertension: the impact of epoprostenol therapyCirculation2002106121477148212234951
   PubMed Web of Science ®Google Scholar
• BarstRJRubinLJMcGoonMDCaldwellEJLongWALevyPSSurvival in primary pulmonary hypertension with long-term continuous intravenous prostacyclinAnn Intern Med199412164094158053614
   PubMed Web of Science ®Google Scholar
• PattersonJHAdamsKFJrGheorghiadeMAcute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failureAm J Cardiol199575326A33A7801859
   PubMed Web of Science ®Google Scholar
• DumbleLJGibbonsSTejpalN15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporineTransplantation1993555112411288497892
   PubMed Web of Science ®Google Scholar
• MohlerER3rdKlugherzBGoldmanRKimmelSEWadeMSehgalCMTrial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudicationVasc Med20005423123711213235
   PubMed Web of Science ®Google Scholar
• SimonneauGBarstRJGalièNContinuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trialAm J Respir Crit Care Med2002165680080411897647
   PubMed Web of Science ®Google Scholar
• WadeMBakerFJRoscignoRDellaMaestraWHuntTLLaiAAAbsolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusionJ Clin Pharmacol2004441838814681345
   PubMed Web of Science ®Google Scholar
• LaliberteKArnesonCJeffsRHuntTWadeMPharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteersJ Cardiovasc Pharmacol200444220921415243302
   PubMed Web of Science ®Google Scholar
• WadeMBakerFJRoscignoRPharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusionJ Clin Pharmacol200444550350915102871
   PubMed Web of Science ®Google Scholar
• McSwainCSBenzaRShapiroSDose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusionJ Clin Pharmacol2008481192518094217
   PubMed Web of Science ®Google Scholar
• Remodulin® [package insert]Silver Spring, MDUnited Therapeutics Corporation2013 Available from: https://http://www.remodulin.com/downloads/remodulin-prescribinginformation.pdfAccessed September 1, 2014
   Google Scholar
• Skoro-SajerNLangIMHarjaEKneusslMPSingWGGibbsSJA clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertensionClin Pharmacokinet200847961161818698881
   PubMed Web of Science ®Google Scholar
• BarstRJGalieNNaeijeRLong-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinilEur Respir J20062861195120316899485
   PubMed Web of Science ®Google Scholar
• BenzaRLTapsonVFGomberg-MaitlandMPomsABarstRJMcLaughlinVVOne-year experience with intravenous treprostinil for pulmonary arterial hypertensionJ Heart Lung Transplant201332988989623953817
   PubMed Web of Science ®Google Scholar
• DesoleSVelik-SalchnerCFraedrichGEwertRKahlerCMSubcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertensionHeart Lung201241659960522920608
   PubMed Web of Science ®Google Scholar
• EwertRHalankMBruchLGhofraniHAA case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapyAm J Respir Crit Care Med2012186111196119823204382
   PubMed Web of Science ®Google Scholar
• OudizRJSchilzRJBarstRJTreprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue diseaseChest2004126242042715302727
   PubMed Web of Science ®Google Scholar
• LangIGomez-SanchezMKneusslMEfficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertensionChest200612961636164316778286
   PubMed Web of Science ®Google Scholar
• TapsonVFGomberg-MaitlandMMcLaughlinVVSafety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trialChest2006129368368816537868
   PubMed Web of Science ®Google Scholar
• MathierMAMcDevittSSaggarRSubcutaneous treprostinil in pulmonary arterial hypertension: Practical considerationsJ Heart Lung Transplant201029111210121720855220
   PubMed Web of Science ®Google Scholar
• Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension – seven sites, United States, 2003–2006MMWR Morb Mortal Wkly Rep200756817017217332729
   PubMedGoogle Scholar
• KallenAJLedermanEBalajiABloodstream infections in patients given treatment with intravenous prostanoidsInfect Control Hosp Epidemiol200829434234918462147
   PubMed Web of Science ®Google Scholar
• KittermanNPomsAMillerDPLombardiSFarberHWBarstRJBloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®Mayo Clinic Proc2012879825834
   PubMed Web of Science ®Google Scholar
• RichJDGlassnerCWadeMThe effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertensionChest20121411364221659437
   PubMed Web of Science ®Google Scholar
• Ventavis^® [package insert]AllschwilActelion Pharmaceuticals Ltd112013 Available from: http://www.4ventavis.com/pdf/Ventavis_PI.pdfAccessed September 1, 2014
   Google Scholar
• OlschewskiHRohdeBBehrJPharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertensionChest200312441294130414555558
   PubMed Web of Science ®Google Scholar
• VoswinckelRGhofraniHAGrimmingerFSeegerWOlschewskiHInhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertensionAnn Intern Med2006144214915016418424
   PubMed Web of Science ®Google Scholar
• OlschewskiHWalmrathDSchermulyRGhofraniAGrimmingerFSeegerWAerosolized prostacyclin and iloprost in severe pulmonary hypertensionAnn Intern Med199612498208248610951
   PubMed Web of Science ®Google Scholar
• OlschewskiHGhofraniHAWalmrathDTemmesfeld-WollbruckBGrimmingerFSeegerWRecovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprostIntensive Care Med19982466316349681789
   PubMed Web of Science ®Google Scholar
• StrickerHDomenighettiGFioriGMombelliGSustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertensionSchweiz Med Wochenschr19991292492392710413827
   PubMedGoogle Scholar
• OlschewskiHGhofraniHASchmehlTInhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study GroupAnn Intern Med2000132643544310733442
   PubMed Web of Science ®Google Scholar
• HoeperMMSchwarzeMEhlerdingSLong-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogueN Engl J Med2000342251866187010861321
   PubMed Web of Science ®Google Scholar
• OlschewskiHSimonneauGGalièNAerosolized Iloprost Randomized Study GroupInhaled iloprost for severe pulmonary hypertensionN Engl J Med2002347532232912151469
   PubMed Web of Science ®Google Scholar
• McLaughlinVVOudizRJFrostARandomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertensionAm J Respir Crit Care Med2006174111257126316946127
   PubMed Web of Science ®Google Scholar
• OpitzCFWenselRWinklerJClinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertensionEur Heart J200526181895190215888496
   PubMed Web of Science ®Google Scholar
• OlschewskiHHoeperMMBehrJLong-term therapy with inhaled iloprost in patients with pulmonary hypertensionRespir Med2010104573174020153158
   PubMed Web of Science ®Google Scholar
• Tyvaso^® [package insert]Silver Spring, MDUnited Therapeutics Corporation2014 Available from: https://http://www.tyvaso.com/pdf/Tyvaso-PI.pdfAccessed September 1, 2014
   Google Scholar
• VoswinckelREnkeBReichenbergerFFavorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studiesJ Am Coll Cardiol20064881672168117045906
   PubMed Web of Science ®Google Scholar
• ChannickRNOlschewskiHSeegerWStaubTVoswinckelRRubinLJSafety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertensionJ Am Coll Cardiol20064871433143717010807
   PubMed Web of Science ®Google Scholar
• VoswinckelRReichenbergerFEnkeBAcute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertensionPulm Pharmacol Ther200821582483218657627
   PubMed Web of Science ®Google Scholar
• McLaughlinVVBenzaRLRubinLJAddition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trialJ Am Coll Cardiol201055181915192220430262
   PubMed Web of Science ®Google Scholar
• BenzaRLSeegerWMcLaughlinVVLong-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extensionJ Heart Lung Transplant201130121327133322055098
   PubMed Web of Science ®Google Scholar
• GalièNHumbertMVachiéryJLEffects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trialJ Am Coll Cardiol20023991496150211985913
   PubMed Web of Science ®Google Scholar
• BarstRJMcGoonMMcLaughlinVBeraprost therapy for pulmonary arterial hypertensionJ Am Coll Cardiol200341122119212512821234
   PubMed Web of Science ®Google Scholar
• WhiteRJTorresFAllenRPharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertensionJ Cardiovasc Pharmacol201361647448123328389
   PubMed Web of Science ®Google Scholar
• Orenitram^® [package insert]Silver Spring, MDUnited Therapeutics Corporation2013 Available from: http://www.orenitram.com/dtc/pdf/Orenitram_Full_Prescribing_Information.pdfAccessed September 1, 2014
   Google Scholar
• LimAWang-SmithLKatesJLaurentAKumarPLaliberteKThe effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteersJ Clin Pharm Ther201338645045523927483
   PubMed Web of Science ®Google Scholar
• PetersonLMarburyTMarierJLaliberteKAn evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairmentJ Clin Pharm Ther201338651852324033615
   PubMed Web of Science ®Google Scholar
• JingZCParikhKPulidoTEfficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trialCirculation2013127562463323307827
   PubMed Web of Science ®Google Scholar
• TapsonVFTorresFKermeenFOral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trialChest201214261383139022628490
   PubMed Web of Science ®Google Scholar
• TapsonVFJingZCXuKFFREEDOM-C2 Study TeamOral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trialChest2013144395295823669822
   PubMed Web of Science ®Google Scholar
• Gomberg-MaitlandMTapsonVFBenzaRLTransition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertensionAm J Respir Crit Care Med2005172121586158916151039
   PubMed Web of Science ®Google Scholar
• VachieryJLHillNZwickeDBarstRBlackburnSNaeijeRTransitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertensionChest200212151561156512006444
   PubMed Web of Science ®Google Scholar
• RubenfireMMcLaughlinVVAllenRPTransition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trialChest2007132375776317400684
   PubMed Web of Science ®Google Scholar
• de Jesus PerezVARosenzweigERubinLJSafety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertensionAm J Cardiol2012110101546155022853986
   PubMed Web of Science ®Google Scholar
• ChannickRNFrantzRPKawutSMA multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprostPulm Circ20133238138824015339
   PubMed Web of Science ®Google Scholar
• EnderbyCYSoukupMAl OmariMZeigerTBurgerCTransition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case seriesJ Clin Pharm Ther201439549650024806480
   PubMed Web of Science ®Google Scholar
• BourgeRCTapsonVFSafdarZRapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertensionCardiovasc Ther2013311384422970909
   PubMed Web of Science ®Google Scholar
• HoeperMMLeuchteHHalankMCombining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertensionEur Respir J200628469169417012628
   PubMed Web of Science ®Google Scholar
• HiremathJThanikachalamSParikhKExercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trialJ Heart Lung Transplant201029213714920022264
   PubMed Web of Science ®Google Scholar
• McLaughlinVVGaineSPBarstRJEfficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertensionJ Cardiovasc Pharmacol200341229329912548091
   PubMed Web of Science ®Google Scholar